Mr. Justin Hanka reports

MINDBIO ADOPTS NEW EQUITY INCENTIVE PLAN

Mindbio Therapeutics Corp. has adopted a new equity incentive plan. The new plan is a 20-per-cent rolling equity incentive plan that provides for the issuance of stock options, restricted share units (RSUs) and deferred share units (DSUs). The new plan replaces the company's old 20-per-cent fixed stock option plan. In connection with the adoption of the new plan, certain employees, consultants and directors of the company agreed to cancel an aggregate of 26,592,250 stock options issued under the old plan. Stock options issued under the old plan that were not cancelled will be governed by the terms of the new plan. The new plan was approved by the directors of the company on April 1, 2025.

Mindbio invites you to join the company in support of creating a brighter future for mental health.

About Mindbio Therapeutics Corp.

Mindbio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home human clinical trials of a psychedelic medicine. MB22001 is Mindbio's lead candidate drug, a proprietary titratable form of lysergic acid diethylamide (LSD) designed for take-home microdosing. Mindbio is a leader in microdosing of psychedelic medicines, and is advancing its drug and technology protocols through clinical trials. Mindbio has developed a multidisciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed phase 1 clinical trials in 80 healthy participants, and has completed a phase 2a clinical trial in patients with major depressive disorder, both trials with positive top-line data reported. Currently under way are two phase 2B trials, one in cancer patients experiencing existential distress and another in patients with major depressive disorder. The company is also approved for multiple phase 1/phase 2B trials in women's health. Mindbio invests in research that forms the basis for developing novel and clinically proven treatments, including digital technologies and interventions to treat debilitating health conditions, such as depression, anxiety and other related mental health conditions.

We seek Safe Harbor.